Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

1.0K
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.0K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

608
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
608
Transcellular Transport of Solutes01:23

Transcellular Transport of Solutes

5.3K
Transcellular transport of solutes is the movement of substances like monosaccharides and amino acids through polarized cells. This transport mechanism is primarily seen in epithelial and endothelial cells aided by membrane transport proteins such as channels and transporters. The tight junctions between these cells confine the membrane proteins to the two sides of the cell. The epithelial cells have distinct apical and basolateral domains. In contrast, the endothelial cells show the luminal...
5.3K
Mutations01:39

Mutations

96.0K
Overview
96.0K
Glucose Transporters01:27

Glucose Transporters

28.0K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
28.0K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

2.2K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stress management reduces severe depression and anxiety symptoms in adults with cystic fibrosis: Results from the coping and learning to manage stress (CALM) intervention.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Same author

The Human Cost of Respiratory Care: Professional Quality of Life and Burnout Across Multidisciplinary Cystic Fibrosis Teams.

Chest·2026
Same author

Advancing Mental Healthcare for Individuals With Cystic Fibrosis in Low- and Middle-Income Countries.

Pediatric pulmonology·2026
Same author

Integrating cognitive behavioral therapy into specialty care for adolescents with cystic fibrosis: a feasibility trial.

Journal of pediatric psychology·2026
Same author

Stakeholder Priorities for Cystic Fibrosis Mental Health Research: A Community and Provider Survey.

Pediatric pulmonology·2026
Same author

Core outcome domains for <i>Mycobacterium avium</i> complex pulmonary disease: a MACCOR study.

ERJ open research·2025

Related Experiment Video

Updated: Mar 21, 2026

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

671

Cystic fibrosis.

Felix Ratjen1, Scott C Bell2, Steven M Rowe3

  • 1Division of Respiratory Medicine, Department of Paediatrics, The Hospital for Sick Children and University of Toronto, 555 University Avenue, Toronto M5G 1X8, Canada.

Nature Reviews. Disease Primers
|May 19, 2016
PubMed
Summary
This summary is machine-generated.

Cystic fibrosis (CF) is a genetic disorder caused by CFTR gene mutations. New therapies targeting the underlying ion channel defect offer hope for improved disease management and patient quality of life.

More Related Videos

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression
08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

1.2K
Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

11.2K

Related Experiment Videos

Last Updated: Mar 21, 2026

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis
05:56

Implementation of Non-invasive Point of Care Transient Elastography for Evaluation of Liver Disease in Pediatric Populations with Cystic Fibrosis

Published on: August 29, 2025

671
Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression
08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

1.2K
Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
08:00

Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study

Published on: April 11, 2018

11.2K

Area of Science:

  • Genetics
  • Molecular Biology
  • Pulmonology

Background:

  • Cystic fibrosis is an autosomal recessive, monogenetic disorder resulting from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
  • CFTR protein dysfunction leads to multi-organ disease, with lung pathology causing the most significant morbidity and mortality.
  • Significant advancements in understanding CFTR mutations and therapeutic strategies have been made over the past 25 years.

Purpose of the Study:

  • To summarize current knowledge on cystic fibrosis pathogenesis and treatment.
  • To provide an outlook on the impact of new therapeutic options on clinical care and research.
  • To highlight the shift towards treatments directly addressing the CFTR ion channel abnormality.

Main Methods:

  • Review of current scientific literature on cystic fibrosis.
  • Analysis of the impact of novel therapeutic strategies.
  • Synthesis of knowledge for future clinical care and research directions.

Main Results:

  • CFTR gene mutations are the cause of cystic fibrosis.
  • Lung disease is the primary cause of mortality in CF patients.
  • Novel treatments targeting CFTR dysfunction are emerging, shifting focus from complication management.

Conclusions:

  • Prenatal diagnostics, newborn screening, and new treatment algorithms are altering CF incidence and prevalence.
  • Emerging therapies directly target the ion channel defect, promising to change disease progression.
  • Future research and clinical care will be significantly influenced by new knowledge and therapeutic advancements in CF.